Alan Sandler
About Alan Sandler
Alan Sandler, M.D., is Chief Development Officer at Revolution Medicines (appointed September 29, 2025), leading global Development across RVMD’s late‑stage RAS(ON) inhibitor portfolio; he previously served as CMO of ALX Oncology, EVP/CMO of Mirati Therapeutics, President & Head of Global Development (Oncology) at Zai Lab, and held senior development roles at Genentech; academically, he led thoracic oncology programs at Oregon Health & Science University, Vanderbilt University, and Indiana University; he earned his M.D. from Rush Medical College and trained in internal medicine and medical oncology at Yale-New Haven Medical Center
Context on RVMD performance: 2024 TSR (cumulative value of a $100 investment since IPO) was $151.35, vs $99.24 (2023), $82.42 (2022), $88.55 (2021), $136.99 (2020) . RVMD had no product revenue and reported a net loss of $600.1M in 2024 and cash, cash equivalents and marketable securities of $2.3B at year-end .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| ALX Oncology | Chief Medical Officer | — | Led clinical strategy and advanced immune‑oncology pipeline |
| Mirati Therapeutics | EVP & Chief Medical Officer | — | Guided development through acquisition by Bristol Myers Squibb |
| Zai Lab Limited | President & Head of Global Development (Oncology) | — | Led global oncology development programs |
| Genentech (Roche) | Senior Development Leadership | — | Drove multiple oncology development programs |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Oregon Health & Science University | Division Chief, Hematology/Oncology | — | Led academic lung cancer programs |
| Vanderbilt University | Medical Director, Thoracic Oncology | — | Directed thoracic oncology clinical programs |
| Indiana University | Medical Director, Thoracic Oncology Program | — | Led thoracic oncology initiatives |
| Rush Medical College / Yale-New Haven | Education & Training (M.D.; IM/Oncology fellowships) | — | Clinical training foundation |
Fixed Compensation
| Component | RVMD Program (proxy-disclosed) | Alan Sandler Status |
|---|---|---|
| Base salary | Fixed cash; reviewed annually vs peer group and scope | Not disclosed (no 8‑K 5.02/offer terms filed) |
| Target annual bonus % | Percent of base (e.g., CEO 75%; other NEOs 40–50% in 2024 context) | Not disclosed |
| Equity mix | Annual grants: ~70% stock options, ~30% RSUs (4‑year vest) | Not disclosed; new-hire grants timing typically first day of month after start |
| Perquisites | None for NEOs; standard benefits and 401(k) match | Not disclosed |
Performance Compensation
| Metric | Weighting | Target | Actual (2024) | Company-wide Payout Factor | Vesting/Timing |
|---|---|---|---|---|---|
| Research & Development (pipeline advancement, pivotal initiations, supply chain, discovery) | 75% | Defined R&D goals | 98% achievement | 130% overall company payout approved by Board | Cash bonus paid; equity vests over 4 years |
| Corporate (financing, commercial build, budget, hiring/retention) | 25% | Defined corporate goals | 32% achievement | 130% overall company payout approved by Board | Cash bonus paid; equity vests over 4 years |
Note: Alan Sandler’s individual targets/bonus outcomes for 2025 have not been disclosed. The table reflects RVMD’s 2024 program design and outcomes used for NEOs .
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Beneficial ownership | Not yet disclosed for Sandler (appointed 9/29/2025; no Forms or proxy tables including him to date) |
| Vested vs unvested | Not disclosed |
| Pledging/Hedging | Company policy prohibits hedging, derivative transactions, margining, or pledging of RVMD equity by officers/directors/employees |
| Ownership guidelines | Not disclosed in 2025 proxy for officers (no guideline table provided) |
| Option/RSU structure | Options vest monthly over 4 years; RSUs vest quarterly over 4 years; grants typically made on the first day of the month following hire/committee meeting |
Employment Terms
- Appointment: Alan Sandler, M.D. appointed Chief Development Officer (newly created role) on September 29, 2025 . No 8‑K Item 5.02 filing with offer-letter economics has been posted; compensation/severance specifics are not yet public .
- Company severance framework (context from DEF 14A for NEOs): Outside change-in-control (CIC), CEO=1.0x salary+target bonus and 12 months COBRA; other NEOs=0.75x salary+target bonus and 9 months COBRA. During CIC window (3 months before to 18 months after), CEO=2.0x salary+target bonus, 18 months COBRA, full equity acceleration; other NEOs=1.0x salary+target bonus, 12 months COBRA, full equity acceleration; no excise tax gross-ups; double‑trigger required . Sandler’s specific terms are pending disclosure.
Investment Implications
- Execution capability: Sandler’s deep lung cancer and oncology drug development leadership (ALX Oncology, Mirati, Genentech) strengthens RVMD’s Phase 3 execution in PDAC/NSCLC and combination strategies, aligning with RVMD’s expanded pivotal program slate and commercial build‑out .
- Alignment/controls: RVMD’s anti‑hedging/pledging policy and 2023 clawback policy reduce misalignment risk and protect pay‑for‑performance integrity, while severance is double‑trigger and no tax gross‑ups (shareholder‑friendly) .
- Disclosure watch‑items: Monitor forthcoming Form 3/4 filings and 2026 proxy for Sandler’s base, target bonus, equity grants, and vesting schedules; track any insider trading plans to assess selling pressure; and follow pivotal trial milestones (RASolute 302/304/303; RASolve 301) that drive performance metrics and potential payouts .
Supporting Data
| RVMD Pay vs Performance – TSR ($ initial $100 investment) | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total Shareholder Return (TSR) | 136.99 | 88.55 | 82.42 | 99.24 | 151.35 |
| RVMD 2024 Financial Highlights | FY 2024 |
|---|---|
| Net Loss ($MM) | (600) |
| Cash, Cash Equivalents & Marketable Securities ($B) | 2.3 |
| Sandler Appointment | Date | Role |
|---|---|---|
| Press release | Sept 29, 2025 | Chief Development Officer |
| RVMD 8‑K Q3 update (corporate summary) | Nov 5, 2025 | Confirms appointment |
Sandler “brings internationally recognized expertise in oncology drug development… and has contributed to several successful drug approvals.” **[https://www.revmed.com/team/alan-sandler-m-d/#:~:text=Alan%20brings%20internationally%20recognized%20expertise,to%20several%20successful%20drug%20approvals.]**